Dear Editor, The Roche and Clinton Foundation HIV/Aids Initiative (CHAI) in Rwanda are well-timed. I was delighted to know that the duo signed an agreement with the Rwandan government in approval of a fundamental Aids project. This project will give children below eighteen months more access to HIV tests, diagnose children at reduced prices and make it possible for Early Infant Diagnosis to be carried out. Laboratory devices to test children and comprehensive products for the collection of dried blood spot samples will also be supplied. Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. It is also world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases. Besides, children in the Sub-Saharan region are particularly vulnerable to the disease. It is therefore crucial that the HIV/Aids status of a child is know early enough so that treatment can be started as soon as possible. I believe that expertise will make a difference for young children and most vulnerable HIV/Aids patients. KIMISAGARA
